PP2A and GSK3 Act as Modifiers of FUS-ALS by Modulating Mitochondrial Transport

Using a genome-wide screening approach, the authors identified Protein Phosphatase 2A (PP2A) and Glycogen Synthase Kinase 3 (GSK3) as novel modifiers of fused in sarcoma-amyotrophic lateral sclerosis.